Tags

Type your tag names separated by a space and hit enter

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Am J Psychiatry. 1998 Jul; 155(7):914-20.AJ

Abstract

OBJECTIVE

The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia.

METHOD

One hundred three previously treatment-resistant patients with schizophrenia diagnosed according to the DSM-III-R criteria were given a prospective 6-week trial of 10-40 mg/day of haloperidol. Eighty-four of them failed to respond to that trial and agreed to be randomly assigned to an 8-week fixed-dose trial of either 25 mg/day of olanzapine alone or 1200 mg/day of chlorpromazine plus 4 mg/day of benztropine mesylate.

RESULTS

Fifty-nine (70%) of the 84 subjects completed the trial. The primary outcome measures were Brief Psychiatric Rating Scale total score and positive symptom score, Scale for the Assessment of Negative Symptoms global score, and Clinical Global Impression score. An analysis of variance for the subjects who completed the study showed no difference in efficacy between the two drugs. Seven percent of the olanzapine-treated patients responded according to a priori criteria; no chlorpromazine-treated patients responded. The olanzapine-treated patients had fewer motor and cardiovascular side effects than the chlorpromazine-treated patients. Extrapyramidal symptoms and akathisia were similar in the two groups, although no antiparkinsonian drugs were used in the olanzapine group.

CONCLUSIONS

Olanzapine and chlorpromazine showed similar efficacy, and the total amount of improvement with either drug was modest. Olanzapine-treated patients had fewer side effects than chlorpromazine-treated patients.

Authors+Show Affiliations

Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore 21228, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9659857

Citation

Conley, R R., et al. "Olanzapine Compared With Chlorpromazine in Treatment-resistant Schizophrenia." The American Journal of Psychiatry, vol. 155, no. 7, 1998, pp. 914-20.
Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998;155(7):914-20.
Conley, R. R., Tamminga, C. A., Bartko, J. J., Richardson, C., Peszke, M., Lingle, J., Hegerty, J., Love, R., Gounaris, C., & Zaremba, S. (1998). Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. The American Journal of Psychiatry, 155(7), 914-20.
Conley RR, et al. Olanzapine Compared With Chlorpromazine in Treatment-resistant Schizophrenia. Am J Psychiatry. 1998;155(7):914-20. PubMed PMID: 9659857.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. AU - Conley,R R, AU - Tamminga,C A, AU - Bartko,J J, AU - Richardson,C, AU - Peszke,M, AU - Lingle,J, AU - Hegerty,J, AU - Love,R, AU - Gounaris,C, AU - Zaremba,S, PY - 1998/7/11/pubmed PY - 1998/7/11/medline PY - 1998/7/11/entrez SP - 914 EP - 20 JF - The American journal of psychiatry JO - Am J Psychiatry VL - 155 IS - 7 N2 - OBJECTIVE: The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia. METHOD: One hundred three previously treatment-resistant patients with schizophrenia diagnosed according to the DSM-III-R criteria were given a prospective 6-week trial of 10-40 mg/day of haloperidol. Eighty-four of them failed to respond to that trial and agreed to be randomly assigned to an 8-week fixed-dose trial of either 25 mg/day of olanzapine alone or 1200 mg/day of chlorpromazine plus 4 mg/day of benztropine mesylate. RESULTS: Fifty-nine (70%) of the 84 subjects completed the trial. The primary outcome measures were Brief Psychiatric Rating Scale total score and positive symptom score, Scale for the Assessment of Negative Symptoms global score, and Clinical Global Impression score. An analysis of variance for the subjects who completed the study showed no difference in efficacy between the two drugs. Seven percent of the olanzapine-treated patients responded according to a priori criteria; no chlorpromazine-treated patients responded. The olanzapine-treated patients had fewer motor and cardiovascular side effects than the chlorpromazine-treated patients. Extrapyramidal symptoms and akathisia were similar in the two groups, although no antiparkinsonian drugs were used in the olanzapine group. CONCLUSIONS: Olanzapine and chlorpromazine showed similar efficacy, and the total amount of improvement with either drug was modest. Olanzapine-treated patients had fewer side effects than chlorpromazine-treated patients. SN - 0002-953X UR - https://www.unboundmedicine.com/medline/citation/9659857/Olanzapine_compared_with_chlorpromazine_in_treatment_resistant_schizophrenia_ L2 - https://ajp.psychiatryonline.org/doi/10.1176/ajp.155.7.914?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -